Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has described immunoproteasome inhibitors reported to be useful for the treatment of systemic lupus erythematosus and arthritis.
Qianhangjiang Pharmaceutical Co. Ltd. has divulged somatostatin peptide analogues acting as somatostatin receptor type 2 (SSTR2) ligands reported to be useful for the treatment of cancer and acromegaly.
Summit Therapeutics Inc. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety coupled to a GTPase KRAS (G12D) targeting moiety through a linker acting as KRAS (G12D) inhibitors and degradation inducers reported to be useful for the treatment of cancer.
Shanghai Jemincare Pharmaceutical Co. Ltd. has synthesized ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
Beijing Primegene Therapeutics Co. Ltd. has disclosed serine/threonine-protein kinase Nek7 inhibitors reported to be useful for the treatment of cancer, inflammatory bowel disease, stroke, osteoarthritis, multiple sclerosis, rheumatoid arthritis, atherosclerosis and Alzheimer’s disease, among others.
Pliant Therapeutics Inc. has described integrin αvβ1, integrin αvβ6 and/or integrin αvβ8 antagonists reported to be useful for the treatment of cancer and fibrosis.
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. has identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase cereblon binding moiety coupled to an EGFR-targeting moiety via a linker reported to be useful for the treatment of non-small-cell lung cancer.
Duality Biologics (Suzhou) Co, Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1)-targeting moiety through a linker reported to be useful for the treatment of cancer.
RSS